Credit: Courtesy INOVIO
Dr. Kate Broderick is a scientist leading the development of a DNA vaccine to treat the novel coronavirus (COVID-19) at INOVIO Pharmaceuticals. As INOVIO s Senior Vice President of Research and Development, Dr. Broderick works on developing and delivering DNA-based medicines to prevent a range of deadly infectious diseases and cancers. A recognized vaccine expert, Broderick, 43, has served as a principal investigator on grants, awards and contracts from leading government agencies and not-for-profit organizations, including the National Institutes of Health and the U.S. Department of Defense. She received her Ph.D. from the University of Glasgow, Scotland, and conducted post-doctoral research at the University of California, San Diego before joining INOVIO in 2006. She lives in San Diego with her husband Steve, 39, and their two children Rory, 8, and Isla, 5. This is her story, as
INO-4800 COVID-19 Vaccine Description
INO-4800 is a DNA vaccine candidate matched to the novel coronavirus SARS-CoV-2, which causes the COVID-19 disease in humans.
INOVIO s INO-4800 is the only nucleic-acid-based vaccine stable at room temperature for more than a year and does not require frozen transport or for years of storage, which are important factors when implementing mass immunizations to battle the current pandemic, says INOVIO.
The INO-4800 vaccine contains the plasmid pGX9501, which encodes for the entire length of the Spike glycoprotein of SARS-CoV-2.
Inovio s proprietary platform hand-held smart device called CELLECTRA® leads the way forward for activation immunotherapy. CELLECTRA uses a brief electrical pulse to open small pores in the cell reversibly to allow the plasmids to enter.
INOVIO s Phase 2 vaccine clinical trials underway
and last updated 2020-12-16 20:48:12-05
SAN DIEGO (KGTV) - Like Pfizer, Moderna, AstraZeneca, and many others, INOVIO Pharmaceuticals has also raced to develop a COVID-19 vaccine this year.
âWeâve been working really hard to move our vaccine through the stages of clinical testing. Some things have taken a little bit longer than we hoped. I think thatâs kind of always the case when youâre trying to go at great light speed,â said Dr. Kate Broderick, INOVIO Pharmaceuticals Senior VP of Research & Development based in San Diego.
Broderick said with funding from the U.S. Department of Defense, the biotech company started its Phase 2 clinical trial evaluating its DNA vaccine candidate, INO-4800.